Spinal muscular atrophy disease: a literature review for therapeutic strategies
- PMID: 20302191
- PMCID: PMC3019038
Spinal muscular atrophy disease: a literature review for therapeutic strategies
Abstract
Currently, there is no cure for the treatment of spinal muscular atrophy (SMA). Based on the available clinical and molecular findings, different therapeutic strategies were tested in vitro and in vivo and clinical trials are ongoing. The main therapeutic direction is focused on the enhancement of SMN expression by increasing the full-length (fl) SMN2 transcript levels, preventing the SMN exon 7 from skipping or from protein stabilizing. In addition, the action of neurotrophic, neuroprotective or anabolic agents is tested and stem cell and gene therapy approaches are in a promising development.
Similar articles
-
Therapeutics development for spinal muscular atrophy.NeuroRx. 2006 Apr;3(2):235-45. doi: 10.1016/j.nurx.2006.01.010. NeuroRx. 2006. PMID: 16554261 Free PMC article. Review.
-
5-(N-ethyl-N-isopropyl)-amiloride enhances SMN2 exon 7 inclusion and protein expression in spinal muscular atrophy cells.Ann Neurol. 2008 Jan;63(1):26-34. doi: 10.1002/ana.21241. Ann Neurol. 2008. PMID: 17924536
-
Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches.Sci Rep. 2015 Jun 30;5:11746. doi: 10.1038/srep11746. Sci Rep. 2015. PMID: 26123042 Free PMC article.
-
Combination of SMN trans-splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy.Hum Gene Ther. 2011 Feb;22(2):135-44. doi: 10.1089/hum.2010.114. Epub 2010 Dec 19. Hum Gene Ther. 2011. PMID: 20804424
-
New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?Int J Mol Sci. 2020 May 7;21(9):3297. doi: 10.3390/ijms21093297. Int J Mol Sci. 2020. PMID: 32392694 Free PMC article. Review.
Cited by
-
Sorting differentiated mammalian cells using deterministic lateral displacement microfluidic devices.Anal Sci. 2024 Oct;40(10):1801-1807. doi: 10.1007/s44211-024-00634-3. Epub 2024 Jul 26. Anal Sci. 2024. PMID: 39060754
-
Comparative effects between bone marrow and mesenchymal stem cell transplantation in GDNF expression and motor function recovery in a motorneuron degenerative mouse model.Stem Cell Rev Rep. 2012 Jun;8(2):445-58. doi: 10.1007/s12015-011-9295-x. Stem Cell Rev Rep. 2012. PMID: 21717132
-
Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy.Hum Mol Genet. 2012 Jan 1;21(1):185-95. doi: 10.1093/hmg/ddr453. Epub 2011 Oct 3. Hum Mol Genet. 2012. PMID: 21968514 Free PMC article.
-
Clinical applications of naturally derived biopolymer-based scaffolds for regenerative medicine.Ann Biomed Eng. 2015 Mar;43(3):657-80. doi: 10.1007/s10439-014-1206-2. Epub 2014 Dec 24. Ann Biomed Eng. 2015. PMID: 25537688 Free PMC article. Review.
-
Disruption of the Survival Motor Neuron (SMN) gene in pigs using ssDNA.Transgenic Res. 2011 Dec;20(6):1293-304. doi: 10.1007/s11248-011-9496-8. Epub 2011 Feb 25. Transgenic Res. 2011. PMID: 21350916 Free PMC article.
References
-
- Melki J, Lefebvre S, Burglen L, Burlet P, Clermont O, Millasseau P, Reboullet S, Benichou B, Zeviani M, LePaslier D. De novo and inherited deletions of 5q13 region in spinal muscular atrophies . Science. 1994;264:1474–1477. - PubMed
-
- Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiology of Disease. 1996;3:97–110. - PubMed
-
- Kaplan JC. Gene table of monogenic neuromuscular disorders (nuclear genome only) Neuromuscular Disorders. 2009;19:77–98. - PubMed
-
- Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype . European Journal of Paediatric Neurology. 1999;3:49–51. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical